Pharmaceuticals giant AstraZeneca is accelerating the shift in its centre of gravity to the US. But it will be seen as a setback for the Labour Government, which is looking to life science firms such as Astra to turbo-charge growth in the UK. Soriot's aim is to lift that to half of the total by 2030, by which time he has pledged to be making $80 billion (£63 billion) a year. He added: 'Losing AstraZeneca from the FTSE 100 would be a blow for the stock exchange – but realistically this looks unlikely in the near-term.' Soriot respects the UK's prowess in life sciences and the company has no intention of moving its share listing to the US.

Source: Daily Mail November 16, 2024 21:57 UTC